Patient’s characteristics
| Characteristics . | Total (N = 15) . |
|---|---|
| Age, median (range), y | 66 (34-74) |
| Male, n (%) | 6 (40) |
| ECOG PS 0, n (%) | 9 (60) |
| High-risk cytogenetics∗, n (%) | 8 (53) |
| BM PC ≥50%† | 9 (69) |
| Extramedullary disease, n (%)‡ | 5 (55) |
| Prior antimyeloma regimens, median (range) | 6 (1-12) |
| Penta-refractory§, n (%) | 14 (93) |
| Prior ASCT, n (%) | 14 (93) |
| Bridging therapy, n (%) | 8 (53) |
| Characteristics . | Total (N = 15) . |
|---|---|
| Age, median (range), y | 66 (34-74) |
| Male, n (%) | 6 (40) |
| ECOG PS 0, n (%) | 9 (60) |
| High-risk cytogenetics∗, n (%) | 8 (53) |
| BM PC ≥50%† | 9 (69) |
| Extramedullary disease, n (%)‡ | 5 (55) |
| Prior antimyeloma regimens, median (range) | 6 (1-12) |
| Penta-refractory§, n (%) | 14 (93) |
| Prior ASCT, n (%) | 14 (93) |
| Bridging therapy, n (%) | 8 (53) |
ASCT, autologous stem cell transplantation; ECOG PS, Eastern Cooperative Oncology Group performance status; PC, plasma cells; PET-CT, positron emission tumography-computed tumography.
del17p, t(4:14), t(14:16), 1q abnormalities.
Percentage of 13 patients with adequate BM sample for evaluation.
Percentage of 9 patients with PET-CT scans at baseline.
Exposure or refractoriness to lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab or isatuximab.